Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Editors Pick
    • Letrozole as good as...

    Letrozole as good as methotrexate for ending ectopic pregnancy: Study

    Written by Medha Baranwal Baranwal Published On 2019-11-28T20:10:44+05:30  |  Updated On 9 Aug 2021 5:40 PM IST

    USA: A recent study has suggested that the use of letrozole, an aromatase inhibitor, can end ectopic pregnancy as effectively as the chemotherapeutic agent methotrexate. The study was presented at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress by Mohamed Mitwally, Odessa Reproductive Medicine Center in Helotes, Texas.


    According to the authors, this could be a huge breakthrough as in contrast to methotrexate, letrozole works hormonally. So, the findings, if confirmed, could do away with the need for chemotherapy regimen for the treatment of ectopic pregnancy.


    An ectopic pregnancy occurs when the fertilized egg, instead of growing inside the uterus, grows outside of it, usually in the fallopian tube. Growing pregnancy can cause the tube to burst that can cause major internal bleeding. This can be life-threatening and requires immediate surgery. A pregnancy can't survive outside of the uterus, so all ectopic pregnancies must end.


    Till now, early ectopic pregnancy was managed with the injection of a drug called methotrexate (Trexall). This can be given if the patients have low levels of hCG -- a hormone your body makes when you're pregnant and there's no damage to the fallopian tube. Methotrexate stops the cells from growing and allows your body to absorb the pregnancy. But the drug does have some side effects, like nausea, vomiting, dizziness, diarrhoea, and stomatitis (mouth and lip ulcers). And most women have abdominal pain a couple of days after the injection.



    "In the absence of estrogen priming, progesterone may not exert its physiological functions due to a negative effect on progesterone receptors. We hypothesized that by inhibiting the estrogen synthetase (the aromatase enzyme), the progesterone would not exert its physiological function in maintaining pregnancy, including ectopic pregnancy," Mitwally and his colleagues explained in their abstract.


    The study involved the assessment of 42 women with undisturbed ectopic pregnancy. Fourteen were treated with methotrexate, 14 were treated with letrozole, and 14 underwent surgery.


    The researchers also measured the metabolic and hormonal effects of the two drugs. Treatment with methotrexate was associated with significantly higher levels of liver enzymes and lower levels of platelets. And more favourable hormone profiles were observed in the patients who received letrozole. Their levels of the pregnancy hormone HCG declined more rapidly than hCG levels in the methotrexate group. Three months after treatment, anti-Mullerian hormone levels were lower in the methotrexate group than they were in the letrozole or surgery groups.


    Read Also: Hyderabad Doctors save ectopic pregnancy patient with rarest Bombay Blood Group


    Key findings of the study include:


    • Complete resolution of ectopic pregnancy occurred in the equal number of patients 12 out of 14 (86%) in each of the study groups.

    • In the methotrexate group, two women required surgery after they became hemostatically unstable.

    • In the letrozole group, one woman required surgery when she became hemostatically unstable and another underwent surgery when her hCG level failed to decrease 4 days after treatment.

    • The metabolic and hormonal effects of the two medications are different -- Women in the methotrexate group experienced a significant elevation in liver enzymes and a significant decrease in platelet levels.

    • Hormone profiles were more favourable in the letrozole group, and hCG levels declined more rapidly in the letrozole group than in the methotrexate group.

    • 3 months after treatment, anti-Mullerian hormone levels were lower in the methotrexate group than in the letrozole or surgery groups.


    Read Also: Management of Ectopic pregnancy and miscarriage: NICE 2019 Guidelines
    "This small study, while preliminary, shows the great promise letrozole holds for the treatment of ectopic pregnancy. Methotrexate has been a medical alternative to surgery for some time. But as an antimetabolite and immune suppressant chemotherapeutic drug, methotrexate comes with toxic effects that may threaten a patient's health and future fertility. Further research is needed, but based on this study, letrozole appears a safe and effective alternative," Bradley Hurst, President of the Society for Reproductive Endocrinology and Infertility remarked, said in a press release.


    The study, "The aromatase inhibitor, letrozole: a novel treatment for ectopic pregnancy," was published in the ASRM journal Fertility and Sterility.


    DOI: https://doi.org/10.1016/j.fertnstert.2019.07.333


    Provided By: ASRM
    American Society for Reproductive Medicine 2019 Congresschemotherapyectopic pregnancyLetrozoleMethotrexateMohamed Mitwally
    Source : ASRM 2019 Congress

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok